Although the lung, liver, or bones are the most common location for distant metastases in breast cancer patients, metastases to the intestinal tract are very rarely recognized in the clinic. We will present an unusual case of colonic metastasis from a carcinoma of the breast that mimics a primary intestinal cancer, along with a thorough review of English language medical literature. Despite the fact that isolated gastrointestinal (GI) metastases are very rare and much less common than benign disease processes or second primaries of the intestinal tract in patients with a history of breast cancer, metastatic disease should be given consideration whenever a patient experiences GI symptoms.

Key Words: Breast cancer, metastasis, colon

INTRODUCTION

Distant metastasis is the most common cause of death in breast cancer patients and these sites often occur in the bone, lungs, brain, and liver. However, metastasis to the GI tract is an unusual presentation despite the fact that intestinal tract metastases are not rare at post mortem examination.\(^1\) The most frequent sites of GI tract involvement are the stomach and the small intestine, while colorectal metastases is very rare.\(^2\) Colorectal metastases can mimic a primary large bowel cancer and may present confusing diagnostic problems.\(^3\)

In this paper, the case of a 43-year-old woman with breast carcinoma developing into colonic metastasis (this was recognized antemortem) is described.

CASE REPORT

A 43-year-old woman underwent right modified radical mastectomy and an axillary curettage in 1997 for a ductal and lobular mixed type carcinoma. She was staged as T2N0M0 postoperatively and found to have been estrogen receptor (ER) negative, progesterone receptor (PR) positive. Following six cycles of adjuvant chemotherapy, she was then treated with a daily dosage of 20 mg tamoxifen (TMX). Thirty-six months after the operation, she began to complain of pelvic pain. A bone scan revealed an increased uptake in the right acetabular area and left proximal femur. The TMX was stopped and a luteinizing hormone-releasing hormone analog (goserelin 3.6 mg monthly) was started due to the metastatic evidence in the bone scan. She also received palliative radiotherapy on the metastatic areas at a dosage of 3000 cGy in ten fractions.

Six months after the diagnosis of bone metastases, the patient was admitted to the regional State hospital because of a one-week history of alteration in her bowel habits, abdominal colicky pain and distension, and nausea/vomiting that had aggravated in the previous 2 days. There was no history of hematemesis, melena, fever, or previous abdominal surgery. On physical examination, the abdomen was distended and bowel sounds were present. There was a tenderness and mild guarding of the lower abdomen. A tender mass was palpated in the right lower quadrant. Rectal examination revealed no abnormalities. No rash, lymphadenopathy, or hernia was detected.
Stool examination for occult blood was negative and tumor markers (CEA, CA19-9) were normal. The erythrocyte sedimentation rate was 14 mm per hour and white blood cell count was $10.6 \times 10^3$ per cubic millimeter. Other blood chemical and enzyme values were normal.

A plain film procedure done in the upright position revealed distended loops of gut with fluid levels being present. Abdominal ultrasonography did not reveal the nature of the mass. Then, abdominal computed tomographic scan showed marked ascending colonic wall thickening extending from the cecum to the proximal portion of the ascending colon, and this caused a narrowing of the lumen and also an infiltration of the pericolic fat (Fig. 1). The scan also revealed distended small bowel loops of gut, free fluid retention in the latero-choanal fascia, perihepatic, and right paracolic gutter and regional lymph nodes smaller than 1 cm in diameter. The patient underwent an exploratory laparotomy, which revealed a large, firm mass in the right abdomen and enlarged indurate lymph nodes in the mesocolon. The distal part of the terminal ileum and the right colon were thickened and indurated. A right-hemicolectomy with end-to-end anastomosis was performed. No evidence of liver, ovarian, uterine, or peritoneal involvement was observed. The postoperative course of recovery was uneventful.

On the examination of the right-hemicolectomy specimen, a thickening and rigidity of the colonic wall extending from the cecum to 6 cm segment of the ascending colon was observed. Microscopic examination revealed a diffuse infiltration by neoplastic cells of the intestinal wall. The tumor cells had invaded the muscularis propria and also the serosa. Seven of the twenty lymph nodes sampled were invaded by tumor. The gross appearance was fully consistent with that of a primary colorectal carcinoma with secondary involvement of local lymph nodes. However, because of a morphological similarity (Fig. 2A, B) to the previous breast cancer and the absence of dysplasia in adjacent colonic epithelium, the histological
findings confirmed metastatic carcinoma. Unlike the original tumor, it was ER positive and PR negative. The cells stained positively for cytokeratin identifying their epithelial origin, and also gross cystic disease fluid protein-15 (GCDFP-15) (Fig. 3). After the operation, the patient was referred to our unit with the diagnosis of metastatic breast cancer. Postoperative abdominal computed tomographic scan and tumor markers (CEA, CA 15-3) were normal. She received 6 cycles of chemotherapy using 5-fluorouracil, adriamycin, and cyclophosphamide. Following her chemotherapy, megestrol acetate at a dosage of 160 mg daily was started. The patient is still alive 7 months after the diagnosis of colonic metastases.

**DISCUSSION**

Only 5% to 15% of breast cancer patients have distant metastases at diagnosis. Although the lymph nodes, lung, liver, or bones are the most common locations for distant metastases, a few cases of GI tract involvement have been reported. Metastases to the intestinal tract from breast carcinoma are very rarely recognized in the clinic setting and its true incidence is not known. However, sixteen percent of patients with breast cancer have GI metastases at postmortem examination. Of these, the most frequent organ involved is the stomach with colon involvement being less common. In a review of the literature, metastatic breast cancer that spread to the colon was found in only 20 of 720 (3%) cases. In most instances, breast cancer metastatic to the large bowel that’s detected during the life of patients have been described as case reports (Table 1).

Taal et al. reported 17 cases of colorectal metastasis from breast cancer over a 15-year period. The primary tumor was usually lobular carcinoma

![Fig. 3. Positive staining with anti-GCDFP-15 (×100).](image)

**Table 1.** English Language Medical Literature Review for Breast Cancer Patients with Colonic Metastases

| Reference (No.) | Patients (n) | Age (yrs) | Time from diagnosis | Primary breast cancer histology | Treatment | Outcome |
|-----------------|-------------|-----------|---------------------|-------------------------------|-----------|---------|
| Taal et al.*(5)  | 17          | 60        | 53 months           | Lobular 15                    | Resection + Systemic (3) | 16 months |
|                 |             |           |                     | Ductal 1                      | Radiotherapy (2) |         |
|                 |             |           |                     | NR 1                          | Systemic (12) |         |
| Schwarz et al. (3) | 1          | 78        | 0.25 years          | Ductal/Lobular                | Resection | NED (19 months) |
| Koutsomanis et al. (6) | 1          | 65        | 4 years             | Ductal                        | Resection + Systemic | NED (36 months) |
| Yokota et al. (2) | 1          | 57        | 10 years            | Ductal                        | Resection | NR      |
| Vaidya et al. (9) | 1          | 56        | 5 years             | Ductal                        | Resection + Systemic | NR      |
| Rabau et al. (4) | 1          | 53        | 7 years             | Lobular                       | Resection | NR      |
| Gifaldi et al. (10) | 1         | 86        | 10 years            | Lobular                       | Resection + Systemic | NR      |
| Voravud et al. (11) | 1         | 74        | 0.5 years           | Lobular                       | Resection | NR      |
| Current case     | 1          | 38        | 5 years             | Ductal/Lobular                | Resection + Systemic | NED (7 months) |

*Data of colonic and rectal metastases together (17 patients).

†Median (range 42 - 76).

*Median survival.

NED, no evidence of disease; NR, not reported.

Yonsei Med J Vol. 47, No. 4, 2006
and patients presented their secondary condition on an average of 53 months after primary treatment. Their average survival time was 16 months. Schwarz et al. reported 7 cases with metastatic breast cancer mimicking a GI tract primary. The average interval between breast cancer and GI metastasis was 6 years and the average survival time after presenting GI symptoms was 12 months. Lobular carcinoma was the predominant histological type and only one out of 7 patients had colonic metastases. For the current case, the interval between primary tumor diagnosis and colonic metastases was 59 months, and she is still alive 7 months after the diagnosis of colonic metastases.

Because of its rarity, its nonspecific clinical presentation and the variable radiographic features, the diagnosis of intestinal metastasis is difficult. In patients with history of breast cancer, isolated GI metastases are less common than benign disease processes or second primaries of the GI tract. Therefore, a history of malignancy does not necessarily imply GI tract metastases. Diagnostic imaging is rarely specific. In order to differentiate primary and metastatic tumors involving the GI tract, histopathological comparison of mammary and GI specimens is mandatory. The morphological similarity to the previous breast cancer and the absence of dysplasia in adjacent colonic epithelium suggests a metastatic growth. As seen in our patient, in the presence of mixed ductal and lobular infiltrative components within the primary, the metastatic growth pattern seems to favor lobular component, but again the mechanisms remain unclear. Immunohistochemistry may also be useful in reaching the correct diagnosis. The ER or PR and GCDFP-15 are usually positive in metastatic breast carcinomas. But it has been reported that up to 30-70% of primary colonic cancers are estrogen receptor positive.

The patient may present with a variety of symptoms including asymptomatic abdominal mass, slight to severe pain or those symptoms suggesting an inflammatory bowel disease or primary GI cancer. Acute presentation with perforation, GI bleeding or bowel obstruction has also been reported. Obstruction of the colon does not commonly occur in cases of right sided lesions. As the lumen of the cecum is large, obstruction due to a primary malignant tumor is rare. However, a circumferential tumor can obliterate the lumen and cause an obstruction. In the current case, the patient presented with evidence of a partial bowel obstruction and abdominal surgery was performed for getting an exact diagnosis and also as a palliative treatment.

Surgery, radiation, and systemic therapy all have a place in the treatment of metastatic breast cancer. While local tumors are typically treated first with surgery and radiation (with an optional systemic therapy as an adjuvant), a multifocal disease process is usually treated with a systemic therapy. But the intestinal involvement of metastatic breast cancer suggests a systemic disease in most cases. Systemic hormonal or chemotherapy, either alone or as an adjunct to surgery, produces a favorable response in patients with GI metastases of breast cancer. If a patient presents with acute or subacute symptoms as in our case, surgery is necessary for palliation and sometimes it is used for an exact diagnosis. Survival after diagnosis of GI metastases is poor with few patients surviving beyond two years. The average survival from time of recurrence is 12 to 16 months.

Isolated GI metastases are very rare and are less common than a benign disease processes or second primaries of the intestinal tract in those patients with a history of breast cancer. But an alert physician should always consider the possibility of a metastatic disease process whenever a patient with such a medical history experiences and presents with GI symptoms.

REFERENCES

1. Cifuentes N, Pickren JW. Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol 1979; 11:193-205.
2. Yokota T, Kunii Y, Kağami M, Yamada Y, Takahashi M, Kikuchi S, et al. Metastatic breast carcinoma masquerading as primary colon cancer. Am J Gastroenterol 2000;95:3014-6.
3. Schwarz RE, Klimstra DS, Turnbull AD. Metastatic breast cancer masquerading as gastrointestinal primary. Am J Gastroenterol 1998;93:111-4.
4. Rabau MY, Alon RJ, Werbin N, Yossipov Y. Colonic metastases from lobular carcinoma of the breast. Report of a case. Dis Colon Rectum 1998;31:401-2.
5. Taal BG, den Hartog Jager FC, Steinmetz R, Peterse H. The spectrum of gastrointestinal metastases of breast carcinoma: II. The colon and rectum. Gastrointest Endosc 1992;38:136-41.
6. Koutsomanis D, Renier JF, Ollivier R, Moran A, el-Haiti AA. Colonic metastasis of breast carcinoma. Hepatogastroenterology 2000;47:681-2.
7. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-7.
8. Klein MS, Sherlock P. Gastric and colon metastases from breast cancer. Am J Dig Dis 1972;17:881-6.
9. Vaidya JS, Mukhtar H, Bryan R. Colonic metastasis from a breast cancer - a case report and a few questions. Eur J Surg Oncol 2002;28:463-4.
10. Gifaldi AS, Petros JG, Wolfe GR. Metastatic breast carcinoma presenting as persistent diarrhea. J Surg Oncol 1992;51:211-5.
11. Voravud N, el-Naggar AK, Balch CM, Theriault RL. Metastatic lobular breast carcinoma simulating primary colon cancer. Am J Clin Oncol 1992;15:365-9.
12. Madeya S, Borsch G. Upper intestinal endoscopy in 188 bronchial cancer patients and 118 breast cancer patients with abdominal symptoms. The GI Metastases Study Group. Med Klin (Munich) 1992;87:631-6.
13. Kaufmann O, Deidesheimer T, Muehlenberg M, Deicke P, Dietel M. Immunohistochemical differentiation of metastatic breast carcinomas from metastatic adenocarcinomas of other common primary sites. Histopathology 1996;29:233-40.
14. Monteagudo C, Merino MJ, LaPorte N, Neumann RD. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Hum Pathol 1991;22:368-72.
15. Bracali G, Caracino AM, Rossodivita F, Bianchi C, Loli MG, Bracali M. Estrogen and progesterone receptors in human colorectal tumour cells (study of 70 cases). Int J Biol Markers 1988;3:41-8.